"What does the competitive and scientific landscape look like?"
Who controls which cohort, and on what evidence. Drug-by-drug commercial posture, prescribing share and payer positioning.
Browse CI →Disease burden, diagnosis rates and the treatment pathway. The market map you build commercial strategy on.
Browse DL →A six-sheet KOL universe and engagement workbook, built gate by gate: sizing, tier classification, scientific influence, engagement readiness, MSL territory coverage, and cross-border network. Every KOL entry carries a verification tag.
Browse KOL →Lecanemab versus donanemab in early AD. CMS amyloid-confirmation coverage and ARIA monitoring as the access gate.
Dupilumab's 70% biologic share against JAK step-edits. A two-tier US payer landscape for IL-4Ra biologics and oral JAKs.
Rezdiffra and Wegovy now split the noncirrhotic MASH label. This is a Year 0 to Year 1 access and retention fight, not a pre-launch window.
Four approved IO agents split 1L NSCLC into three PD-L1 cohorts. Pembrolizumab holds an estimated 52% share ahead of 2028 patent expiry.
US NSCLC segments by histology and biomarker before it segments by drug. This maps where patients are actually diagnosed and tested, and where the gap between diagnosis and treatment costs them.
Tirzepatide 20.9% versus semaglutide 15.3% weight loss. The Medicare coverage gap and commercial step-edit reality.
Iptacopan oral pivot versus the anti-C5 IV class. Orphan-drug exclusion from IRA negotiation (US), NICE HST (UK) and SFDA lag (GCC).
PNH diagnosis pathway, FLAER flow-cytometry bottleneck and the treated-prevalent pool across US centres.
Tirzepatide takes 41% of new GLP-1 starts; SELECT CV indication and IRA negotiation reshape US formulary access.
From zero disease-specific drugs to five in three years: how endothelin, complement and APRIL inhibitors are redrawing the IgAN market.
The prophylaxis class is fracturing along route: oral berotralstat and the first oral on-demand agent against a still-injectable antibody field.
Tafamidis's ATTR-CM monopoly meets acoramidis — while the orphan-drug exclusion keeps the stabilizer class out of IRA price negotiation.
Tc-PYP scintigraphy, not biopsy, is now the diagnostic gate in ATTR amyloidosis. This maps the ATTR-CM versus ATTR-PN split and the wild-type/hereditary divide across a largely undiagnosed population.
US IgA nephropathy has shifted from RAS-blockade supportive care to five disease-modifying therapies. This maps the epidemiology and the biopsy-and-proteinuria diagnostic gate that still controls who reaches them.
HAE pathophysiology, the Type I/II split, attack burden and the diagnostic-delay problem that defines the US in-market landscape.
Neuromuscular-junction autoantibody biology, the AChR/MuSK/seronegative split, and the crisis burden that defines US gMG.
Three novel mechanisms in 24 months — FcRn antagonists vs C5 inhibitors, and the AChR+ vs MuSK+ line that segments the market.
SCD epidemiology, genotype mix, VOC and organ-damage burden, and the 22-year life-expectancy gap across the US in-market population.
Pegunigalsidase now challenges Fabrazyme's two-decade lead in US Fabry disease. Two IV enzyme replacement therapies meet an oral chaperone only ~35–50% of patients can take.
Gaucher type 1 epidemiology, the Ashkenazi Jewish founder burden, GBA1 genotype–phenotype, and the 20-fold Parkinson's risk.
US incidence 1 in 15,700, de novo SCN1A genetics, and one of the highest SUDEP rates documented in epilepsy.
Five FDA-approved Gaucher type 1 therapies (three IV enzyme replacement vs two oral substrate reduction) and eliglustat's oral first-line pivot.
Fabry disease splits into classic childhood-onset and a largely undiagnosed later-onset cardiac form. An X-linked organ timeline and the ~35–50% amenable-mutation gate decide who is treatable.
SMN1/SMN2 biology, the Type 1–4 severity spectrum, and how newborn screening splits SMA into pre-symptomatic and symptomatic populations.
Two Dec-2023 gene therapies (Casgevy, Lyfgenia) reset a ~100,000-patient market, while voxelotor's 2024 withdrawal thins the oral field.
Cold agglutinin disease is a rare classical-complement autoimmune haemolytic anaemia driven by cold-reactive IgM. This separates primary CAD from cold agglutinin syndrome and sizes the US haemolysis burden.
GAA-deficiency biology, the LOPD-versus-IOPD split, the years-long diagnostic delay, and newborn screening across the US Pompe population.
Sutimlimab (Enjaymo) is the only FDA-approved CAD therapy — competing against off-label rituximab-based standard of care, not a branded rival.
Fenfluramine leads on efficacy, cannabidiol anchors the lower-cost branded option, and stiripentol holds the adjunct niche.
Three mechanisms chase one SMN target: a one-time $2.125M gene therapy, chronic intrathecal ASO, and daily oral. Newborn screening resets the battlefield.
Two next-generation ERTs are moving to displace alglucosidase alfa in US late-onset Pompe disease. Avalglucosidase alfa and cipaglucosidase alfa plus miglustat now define the competitive set.
The MASLD-to-MASH-to-F2-F3 funnel, NASH-CRN fibrosis staging, and the FIB-4-to-elastography diagnostic gap behind the 6.7M label-eligible pool.
US atopic dermatitis epidemiology — 16.5M adults, the moderate-to-severe pool, and the atopic march that frames the biologic-eligible segment.
38.4M US adults, an 8.7M undiagnosed pool, and complication burden driving GLP-1 and SGLT2 organ-protection strategy.
US Alzheimer's staging, the amyloid-confirmation diagnostic pathway, and the FDA-cleared plasma pTau-217 blood test resizing the addressable pool.
US adult obesity at 41.9% (CDC NHANES). BMI-class distribution, severe-obesity burden, and the comorbidity segments that drive coverage.
Two 2024 approvals moved the COPD maintenance fight past the inhaler for the first time in a decade. Ensifentrine and dupilumab split the market into an inhaler base and a biology-defined add-on tier.
COPD is a large, under-diagnosed, exacerbation-driven US disease that has just become biomarker-stratified. The blood eosinophil count now decides which of ~14 million diagnosed adults can reach a biologic.
Six mechanisms now compete for moderate-to-severe plaque psoriasis in the US, and the efficacy bar has moved from PASI 75 to PASI 90. IL-17A, dual IL-17A/F, IL-23p19, IL-12/23, TNF and oral TYK2 all hold ground.
Psoriasis affects about 3.0% of US adults, roughly 7.55 million people. Only the moderate-to-severe minority reaches the systemic and biologic therapies that define the commercial market.
Only ribociclib has posted consistent overall-survival wins in the three-way first-line CDK4/6 contest. MONALEESA-2 showed 63.9 versus 51.4 months (HR 0.76). The real competition has moved downstream, where 2023 approvals of an oral SERD and an AKT inhibitor carve the post-CDK4/6 line by biomarker.
HR+/HER2- is the largest breast cancer subtype, roughly 68% of the estimated 317,000 new US invasive female cases in 2025. Most present early and are curable, but 20-30% recur to metastatic disease where five-year survival falls to about a third, making biomarker testing (ESR1, PIK3CA) the fork that determines the treatment path.
Tafamidis's ATTR-CM franchise meets acoramidis under NICE — which now tells clinicians to pick the least-expensive stabiliser.
Anti-C5 IV therapy holds the GCC PNH market under NPHC and MOH specialist-centre gating. Iptacopan's 82.3% haemoglobin-response rate has not reached a single GCC formulary.
Novel IgAN agents are registered across the GCC but not yet formulary-listed. Nephrology specialist centres and the private hospital market are the fastest access channel, while biopsy capacity limits diagnosis.
GCC HAE management is acute-only, with prophylaxis penetration near zero. More than 85% of patients are undiagnosed, and NPHC coverage for lanadelumab would be the access trigger for the region's largest market.
ATTR-CM in the GCC is a pre-commercial opportunity gated by diagnosis, not by drug access. Tafamidis is SFDA-registered and tender-priced 80-90% below US list, but Tc-PYP scintigraphy runs at fewer than 8 centres.
GCC Dravet prescribing runs opposite the US and EU hierarchy. Cannabidiol is de-facto inaccessible under narcotics law, so stiripentol is the specialist standard of care.
IgAN doesn't qualify for the ultra-rare HST track, so both novel agents must clear the standard £20,000-30,000/QALY bar. Both sit in Named Patient access ahead of their NICE decisions.
GCC carries one of the highest per-capita SCD burdens globally: ~140,000 patients in Saudi Arabia alone. Both novel disease-modifiers hit regulatory trouble in 2023-2024, leaving a 25-year-old generic as the only agent with a stable market position.
GCC is a two-ERT Fabry market, with agalsidase alfa via the EMA pathway alongside agalsidase beta. Migalastat's oral advantage, covering 35-50% of patients, is bottlenecked by the single GCC lab that can run the amenable-mutation assay.
All three SMA mechanisms are formulary-listed across the GCC. Outcomes-based rebate contracts now anchor Zolgensma's ~$1.5-1.8M price to a 24-month motor milestone, after an NBS expansion generating 60-80 new gene-therapy candidates a year.
Nexviazyme beat Lumizyme on 6-minute-walk distance in COMET, but NPHC has set no switch criteria. So 80-120 GCC ERT patients mostly stay on the 2006-era standard.
Pegunigalsidase's suboptimal-responder recommendation (TA915) reshapes NHS-commissioned Fabry therapy. It sets oral migalastat against IV enzyme replacement across the UK treated population.
Crizanlizumab's EMA/MHRA withdrawal leaves a VOC-prevention gap. Casgevy's NICE recommendation is the watershed NHS gene-therapy access event — Lyfgenia has no UK regulatory status.
The UK ran Europe's first national SMA newborn-screening programme. All three therapies are NICE-recommended with commercial arrangements, across a living UK cohort of ~1,000 patients in four disease types.
UK HAE Alliance genetic testing, an 87% attack-rate reduction on lanadelumab, and the NICE TA606 prophylaxis standard defining NHS management.
Leeds National Registry data, FLAER access without referral, and the 30% PNH-aplasia overlap defining the NHS commercial picture.
A single five-centre South West England consortium tracks 666 UK patients across all three approved CDK4/6 inhibitors. That kind of coordinated, multi-centre evidence generation is exactly the institutional signal this workbook sizes before any individual name enters it.
A ~25% inadequate-ERT-responder subset defines the next-generation enzyme-replacement opportunity in UK Pompe. The UK Pompe Consortium's shared-care network sits against a 3–8 year late-onset diagnostic delay.
England's NICE has issued three positive technology appraisals funding HAE prophylaxis since 2019 (TA606, TA738, TA1101). The two newest MHRA-licensed agents, donidalorsen and sebetralstat, remain in NICE appraisal with no confirmed final NHS funding decision.
SCN1A molecular confirmation gap, the cannabidiol regulatory restriction, and the stiripentol-backbone standard of care across GCC paediatric neurology.
A ~4,000-patient UK gMG treatment gap remains unresolved. Efgartigimod's June 2025 NICE rejection (TA1069) left it open, against NHS neuromuscular network diagnostics.
Vutrisiran's TA868 PAS-backed approval is reshaping UK ATTR identification and treatment. It joins NICE-commissioned tafamidis access (TA696, updated by TA984) and a 30-centre Tc-PYP diagnostic pathway.
KFSH&RC, AUH, and Hamad Medical Corporation anchor a GCC HAE specialist community that SACIA sizes at just 6-10 physicians regionwide. That concentration is exactly what this workbook sizes before any individual name enters it.
The National Amyloidosis Centre holds the clinical-expert seat at every NICE ATTR appraisal to date. This workbook sizes the UK ATTR KOL network before a name enters it: NAC's 400-500-patient ATTRv surveillance registry, the separate UCL and Queen Elizabeth Hospital Birmingham National ATTRv Registry tracking approximately 800 patients, and the roughly 30 NHS centres running Tc-PYP scintigraphy nationally.
A five-institution Saudi consortium across Riyadh, Jeddah and Dammam tracked 44 Dravet patients on stiripentol combination therapy. That kind of coordinated, cross-city publication is exactly the institutional signal this workbook sizes before any individual name enters it.
Four London teaching hospitals anchor roughly 6,000 of the UK's 15,000-17,000 sickle cell patients. Barts, King's, Imperial and Homerton, with Birmingham Heartlands, Manchester, Bristol and Nottingham forming the next ring. That eight-centre structure is exactly the institutional signal this workbook sizes before any individual name enters it.
Four NHS Highly Specialised Services networks and six designated gene-therapy centres carry the UK SMA treatment pathway. This workbook sizes that institutional structure, plus the Bristol Institute of Child Health attenuation-cohort follow-up, before any physician name enters it.
HAS reimburses iptacopan second-line only, after at least six months on a C5 inhibitor, while ravulizumab holds first-line. France split the anti-complement class by line of therapy, not by price.
The ERT infusion access gap across GCC metabolic centres defines the Pompe opportunity. Newborn screening is expanding for infantile-onset disease, while late-onset still takes a limb-girdle diagnostic detour.
GCC SMA incidence runs 1:6,000–8,000 births, with newborn screening now covering up to 90% in leading states. An 800–1,200-patient pre-NBS-era Type 2/3 cohort defines the chronic-therapy opportunity.
The thyroid-disease diagnostic confounder, specialist neurologist concentration, and the FcRn antagonist access pathway across GCC neurology practice.
UK Renal Registry data, the ACEi/ARB-first Renal Association pathway, and the NHS economic case for novel agents built on £40–50M annual ESRD cost.
All three SMA therapies cleared NICE with confidential PAS. The UK's 2021 newborn screening programme is now the real access lever, shifting competition to physician and family preference.
HAE family cascade screening opportunity, laryngeal attack burden, and the prophylactic therapy access gap across GCC specialist centres.
The UK has Europe's largest SCD population at 15,000–17,000 patients. Newborn screening has made diagnosis near-universal since 1999, and NICE's recommendation of Casgevy (TA1044) will define UK access to a functional cure.
Premarital screening impact, the adult transition care gap, and the gene therapy access horizon across one of the world's highest per-capita SCD burdens.
KFSH&RC runs the only HEK293 amenable-mutation assay in the GCC. Its formulary committee recommendation drives NPHC coverage decisions for every Fabry disease treatment. That kind of single-institution gatekeeping is exactly the concentration this workbook sizes before any individual name enters it.
Just 10-15 neuromuscular neurologists across six named GCC referral centres manage 70-80% of confirmed generalised myasthenia gravis. That concentration is exactly what this workbook sizes before any individual name enters it.
All three UK PNH agents cleared NICE via the standard Technology Appraisal route, not the ultra-rare one. Ravulizumab (TA698), iptacopan (TA1000) and crovalimab all took it. Convenience and switch dynamics, not pathway-driven affordability, now determine NHS share.
Arabian Peninsula founder mutations, the female diagnosis gap, and the HEK assay bottleneck limiting oral chaperone therapy access across the GCC.
Four designated GCC centres carry nearly all regional SMA gene-therapy and specialist referral activity. KAMC and KFSH&RC in Riyadh, Sidra Medicine in Doha, and SKMC in Abu Dhabi. This workbook sizes that institutional concentration before any individual name enters it.
Six to eight named metabolic centres across the GCC hold ERT infusion capacity for Pompe disease. KFSH&RC leads with roughly 120 patients over 15 years. That kind of institutional concentration is exactly what this workbook sizes before any individual name enters it.
Fewer than 25 consultants manage over 90% of the UK's PNH caseload. They sit across five NHS Highly Specialised Services centres anchored by the Leeds National PNH Service. That kind of institutional concentration is exactly the signal this workbook sizes before any individual name enters it.
IgAN diabetes-masking effect, the kidney biopsy bottleneck, and the ESRD progression gap across GCC nephrology practice.
The NHS runs the most treatment-advanced Dravet pathway in Europe. Free SCN1A testing on GMS, a NICE-defined CBD-then-fenfluramine algorithm, and 25 paediatric epilepsy HSS centres underpin it.
An estimated 800-patient UK Fabry cohort has both NHS-commissioned ERT and NICE HST4-recommended oral chaperone therapy. The NHS lysosomal-storage-disorder specialist network and UK Fabry Outcome Survey longitudinal data track it.
PNH diagnostic pathway, FLAER flow-cytometry bottleneck and the undiagnosed clonal pool across GCC specialist centres.
Germany has no confirmed PNH prevalence data of its own. The DGHO's Onkopedia guideline borrows an estimate from British and French registries, and diagnosis funnels through just two national referral centres.
France's national hospitalisation database puts PNH prevalence near 1 in 94,000, or 897 patients from 2018 to 2022. That is lower than the 16-per-million figure Germany's DGHO Onkopedia guideline borrows from French and UK registries.
Six NHS centres concentrate the UK's refractory Dravet syndrome cohort. Great Ormond Street, Bristol, Alder Hey, Birmingham Children's, Leeds and Newcastle. The British Paediatric Neurology Association's Dravet working group shapes NICE evidence review 18-24 months ahead of submission, and that institutional network is what this workbook sizes first, not a roster of named physicians.
Iptacopan's orphan-drug status let it clear AMNOG with an established additional benefit and a substantial quality-of-life finding. Ravulizumab, tested on Germany's only PNH-specific G-BA review to date, found no added benefit at all.
A six-physician BIMDG subcommittee advises NICE directly on Pompe disease. It sits at the centre of a five-centre UK Pompe Consortium and an eight-centre NHS Highly Specialised Service network. That kind of institutional concentration is exactly what this workbook sizes before any individual name enters it.
The Renal Association's IgAN guideline committee, not any single physician, sets the reference point NICE checks against. This workbook sizes that committee and the network behind it before individual outreach begins.
Only three GCC institutions run structured adult sickle cell programmes for 200,000-250,000 patients. KFSH&RC, KAMC and AUH. That three-centre concentration, anchored by the KFSH&RC Dammam flagship and 12+ MOH regional centres in Eastern Province, is exactly the institutional signal this workbook sizes before any individual name enters it.
Saint-Louis Hospital anchors France's MaRIH-coordinated PNH reference network of 14 competence centres. Only 24 of the 50-plus centres in the national clone-observatory network actively report into it. That kind of institutional structure is exactly what this workbook sizes before any individual name enters it.
A 9,146-patient US real-world study found no significant survival difference between palbociclib, ribociclib, and abemaciclib. When the drugs perform equivalently, KOL guidance decides which one gets prescribed, not clinical data.
No novel biologic is yet NHS-commissioned for generalised MG. Eculizumab's manufacturer withdrew its 2020 NICE appraisal before a verdict, and NICE rejected efgartigimod outright in 2025 — leaving rozanolixizumab as the FcRn class's last untested NICE bid.
Five NHS specialist centres manage more than 90% of UK HAE patients. Sheffield, Cambridge, Birmingham, Guy's and St Thomas', and Manchester. That concentration is what this workbook sizes before any physician enters the K1-K6 gate structure.
Royal Free London's National Fabry Service was NICE's appointed clinical expert twice over. It advised on both migalastat's HST4 and pegunigalsidase alfa's TA915, across a network of five named NHS lysosomal storage disorder centres. That repeated appointment is exactly the institutional signal this workbook sizes before any individual name enters it.
A 30-centre NHS neuromuscular network coordinated through Muscular Dystrophy UK carries UK myasthenia care. That network, plus a 3,000-member Myasthenia Gravis Association UK patient registry, is the institutional signal this workbook sizes before any individual name enters it.
KFSH&RC maintains the only GCC-wide ATTRv genetic registry and houses the region's nuclear cardiology programme. Fewer than 8 named cardiology and scintigraphy centres region-wide, spanning KAMC, AUH, HMC Doha, and OCCI Muscat, define a small institutional field this workbook sizes before any individual name enters it.
GCC IgA nephropathy expertise concentrates in five named tertiary centres. Roughly 300 practising nephrologists work the region, of whom 30 to 50 carry glomerular-disease subspecialty interest. This workbook sizes that concentrated institutional base before any individual name enters it.
ATTR-CM diagnostic abyss, Arabian Peninsula TTR variant registry, and the referral-pathway delay across GCC cardiology centres.
Avalglucosidase alfa's NICE recommendation (TA821) puts it against entrenched alglucosidase alfa. NHS switch criteria and the Pombiliti queue position define the next 18 months of UK access.
Seven institutions across Riyadh, Jeddah, Dubai and Abu Dhabi hold the GCC's confirmed PNH caseload. Just 5 to 8 physicians function as genuine adoption gatekeepers. That kind of concentration is exactly what this workbook sizes before any individual name enters it.
Cannabidiol and fenfluramine anchor the NHS-commissioned NICE algorithm; stiripentol still holds a backbone role. New entrants must beat an entrenched three-drug sequence, not just show efficacy.
NPHC formulary criteria for the FcRn class don't yet exist, so pyridostigmine and steroids still treat 85%+ of GCC patients. Efgartigimod reached GCC neurology centres via SFDA and MOH UAE registration in 2023.